Earnings call transcript: Sysmex Corporation reports Q4 2025 earnings

Sysmex reported record FY2025 revenue of JPY 364.4 billion and operating profit of JPY 22.7 billion, beating its revised outlook by JPY 2.7 billion. However, profit attributable to owners was only JPY 500 million due to a JPY 10.5 billion FX valuation loss, which weighed on sentiment and the stock. For FY2026, the company guides for revenue of JPY 359.7 billion and operating profit of JPY 27 billion, while keeping the annual dividend unchanged at JPY 42 per share.

Analysis

The key read-through is not the earnings miss optics; it is that Sysmex is transitioning from an FX-battered, optics-heavy story into a cleaner operating leverage story over the next 2-3 quarters. The market is likely over-anchoring on the yen-denominated net income noise, but the more important signal is that the core margin engine is recovering even as the legacy drag from CGM transfer rolls off. That creates a mechanically easier compare for FY26 and raises the probability of a sequence of upward revisions if foreign exchange stays even mildly supportive.

The second-order winner is any supplier or adjacent healthcare-IT and diagnostics exposure tied to the company’s portfolio simplification. Management is actively reallocating capital away from lower-return assets and into higher-ROIC niches, which typically compresses revenue growth in the short run while improving multiple quality. That should also reduce procurement, logistics, and FX complexity over time; in other words, the business becomes less cyclical than the headline revenue trajectory implies. Competitors still exposed to U.S. instrument demand or stagnant hospital capex are more vulnerable to share loss if Sysmex’s product mix and pricing discipline hold.

The main risk is timing: the stock can still de-rate for several weeks if the market insists on marking the company to near-term yen strength and low reported EPS rather than forward operating profit. The reversal catalyst is a combination of stable FX, a second-quarter confirmation that CGM-related drag has fully lapped, and any evidence that U.S. instruments are inflecting from replacement-only spending toward discretionary demand. If that happens, the gap between reported earnings and economic earnings should narrow sharply, and the current premium valuation becomes easier to defend.

Contrarian view: consensus may be too focused on "expensive stock, weak net income" and too dismissive of the asset mix change. This is the kind of setup where the right question is not whether FY25 looked messy, but whether FY26+ operating margin can re-rate the business quality enough to offset low top-line growth. If management delivers even modest upside to the 27bn yen operating profit target, the stock could rerate faster than the market expects because the earnings base is so depressed relative to operating performance.

Key Decisions for Investors

• Long Sysmex on a 1-3 month horizon if available via ADR/local listing equivalent: enter on post-earnings weakness rather than strength; target a rerating as FY26 guidance confidence improves, with stop-loss if FX turns sharply against the yen and operating commentary deteriorates.
• Use a pair trade: long Sysmex / short a higher-beta healthcare equipment or diagnostics name with greater U.S. capex exposure over the next 2 quarters. The thesis is that Sysmex has better earnings quality and more visible margin expansion while the short leg is more exposed to demand slippage.
• Buy near-dated upside calls or call spreads into the next quarter if the stock remains depressed after the print. Risk/reward improves if the market is underpricing the first clean beat on operating profit once CGM drag is fully normalized.
• Avoid chasing the stock on the net income headline; wait for confirmation that operating profit is translating into reported earnings after FX normalization. The cleaner entry is after the market finishes de-risking the valuation overhang.
• If you already own the name, hedge near-term FX sensitivity with a yen-strength overlay or reduce position size until the next quarterly update confirms that internal loan valuation noise is no longer masking core performance.